1058 - Cisplatin + vinorelbine (DDP + VNB) administered in 60 cases of recurrent/metastatic salivary gland malignancies (RMSGM): final report

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer agents
Head and Neck Cancers
Therapy
Biological therapy
Presenter Oliviero Ostellino
Authors O. Ostellino1, M. Airoldi2, M. Garzaro3, F. Pedani2, L. Raimondo3, G. Riva4, S. Carnio2, G. Pecorari3, G. Fora2, C. Giordano3
  • 1Sc Oncologia 2, San Giovanni Battista Hospital, 10126 - Turin/IT
  • 2Medical Oncology Division - Medical Oncology Department, San Giovanni Battista Hospital, 10126 - Turin/IT
  • 31st Ent Division - Physiopathology Department, University of Turin, 10126 - Turin/IT
  • 4Physiopathology Department, University of Turin, 10126 - Turin/IT

Abstract

Background

RMSGM are not amenable to the usual treatment with surgery and post-operative radiotherapy. The role of chemotherapy (CT) for RMSGM is palliative only. VNB showed moderate activity in our experience (Bull Cancer 85:892; 1998) and in a randomized phase II trial we had demonstrated that the DDP + VNB combination had a better outcome than VNB alone (Cancer 91:541; 2001). In this abstract we report the final results of this combination in 60 cases.

Methods

From April 2001 to February 2009, 60 cases with RMSGM were enrolled. All patients received the following regimen: DDP 80 mg/sm d.1 + VNB 25 mg/sm d. 1,8 every 3 weeks. The study foresees a maximum of 6 cycles.

Results

Patients characteristics were as follows: 35 males (58%) and 25 females (42%); median age: 56 yrs (range 20-68); median ECOG PS: 1 (0-2); histology: adenocarcinoma 15 (25%), adenoid cystic ca. 34 (57%), others 11 (18%); site of disease: local 30 (50%), mts +/- local 30 (50%). Forty-two pts received DDP + VNB as first line CT (70%) while 18 pts (30%) had the combination as second-line CT (30%). After a median of 5 cycles of first line DDP + VNB responses were: 3 CR (7%), 10 PR (24%), 14 NC (33%) and 15 PD (36%). After a median of 4 cycles of second line CT responses were: 0 CR; 1 PR (5%), 6 NC (33%) 11 PD (62%). Median survival: 10 months (3-29) for first line CT; 4 months (1-12) for second line CT. G3-4 toxicity: neutropenia (20%), anemia (12%), nausea/vomiting (12%), peripheral toxicity (3%).

Conclusions

DDP + VNB is an effective first line CT in RMSGM; second line CT has a low palliative activity. Toxicity seems acceptable. This regimen could be suitable for an integration with new biologic target agents.

Disclosure

All authors have declared no conflicts of interest.